ORTHOPEDIATRICS CORP
Close on Oct 19, 2026
- Market cap
- $529.79M
- P/E (TTM)
- –
- Dividend yield
- –
About Orthopediatrics
Surgical & Medical Instruments & Apparatus, SIC 3841
OrthoPediatrics Corp. is a medical device company that develops, manufactures, and markets anatomically appropriate implants, surgical instruments, and specialized bracing products for children with orthopedic conditions. The company also provides non-surgical clinical care through a network of orthotic and prosthetic clinics. Its offerings address three primary categories: trauma and deformity correction, scoliosis, and sports medicine. OrthoPediatrics designs its systems to accommodate pediatric anatomy and protect children's growth plates, serving pediatric orthopedic surgeons, caregivers, and pediatric hospitals.
The company is headquartered in Warsaw, Indiana. It sells its systems in the United States and across more than 75 international countries, operating direct sales channels, independent agencies, and stocking distributor networks. Additionally, the company maintains operating entities and facilities in multiple countries, including warehouses in Australia, Germany, and the Netherlands, alongside orthotic and prosthetic clinics in various United States locations and Ireland.
Summary of the business section of Orthopediatrics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ORTHOPEDIATRICS CORP
- Founded
- 2006
- Headquarters
- Warsaw, IN
- Address
- 2850 Frontier Drive 46582
- Phone
- (574) 268-6379
- Website
- orthopediatrics.com
- Employees
- 602, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- KIDS
- Exchange
- Nasdaq
- IPO date
- Oct 12, 2017
- Shares outstanding
- 26M, Aug 4, 2026
- Public float
- $362.50M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1425450
- CUSIP
- 68752L100
- ISIN
- US68752L1008
- LEI
- 5493000KUTPFGOPAT717
- EIN
- 26-1761833
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David R. Bailey | President and CEO, Director | 417,160 |
| Fred Hite | COO and CFO, Director | 277,477 |
| Daniel J. Gerritzen | General Counsel and Secretary | 147,054 |
| Gregory A. Odle | President of Scoliosis | 187,735 |
| Joseph W. Hauser | Pres. Trauma & Def. Correction | 194,767 |
| David R. Pelizzon | Director | 6,246,148 |
| Kelly Laine Fischer | Director | 15,781 |
| Mark C. Throdahl | Director | 201,814 |
| Samuel D. Riccitelli | Director | 31,859 |
| (Reynolds) Marie C. Infante | Director | 31,202 |
| Bryan W. Hughes | Director | 32,663 |
| Jimmy Duane McDonald | Director | 24,568 |
| George Sinclair Mitchell Dyer | Director | 24,568 |
| Harold Ruf | Director | 22,237 |
| Terry D. Schlotterback | Director | 29,165 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David RBailey | $3.33M | $1.92M | $1.84M | $30 | $75000 |
| FY2024 David RBailey | $3.66M | $2.47M | $1.88M | $56 | $75000 |
| FY2023 David RBailey | $2.72M | $2.21M | $1.52M | $79 | $72000 |
| FY2022 David RBailey | $1.28M | $826.32K | $1.09M | $96 | $75000 |
| FY2021 David RBailey | $906.05K | $1.46M | $784.91K | $145 | $100000 |
| FY2021 Mark C.Throdahl | $718.03K | $1.38M | $784.91K | $145 | $100000 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 602 full-time employees, 43 of whom were engaged in research and development and 109 of whom were engaged in sales and marketing.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 1, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 6, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 20, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 5, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 12, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 11, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |